5 results about "Cholesterol metabolism" patented technology

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

This invention belongs to the field of pharmaceutical technology, and particularly relates to a silicon-based preparation for regulating intestinal flora to improve cholesterol metabolism and its preparation method. The method includes: S1, providing pharmaceutical-grade water-soluble silica raw material; S2, diluting the water-soluble silica raw material with sterile deionized water, stirring at 100-200 r / min for 10-20 min at 20-25°C, and preparing low-dose and high-dose silicon-based preparations respectively. This invention addresses the shortcomings of existing cholesterol-lowering drugs, such as muscle toxicity and new-onset diabetes, caused by long-term use, by providing a silicon-based preparation using pharmaceutical-grade water-soluble silica as a raw material. By limiting the content of metasilicic acid and silica in the raw material, controlling the heavy metal impurity content to ≤10 ppm, and combining sterile deionized water dilution with precise stirring conditions and pH control, the high purity and stability of the preparation are ensured.

Methods and uses of compositions (e.g., comprising one or more microbial strains, one or more components (e.g., microbial components), one or more metabolites (e.g., microbial metabolites) or any combination thereof) for preventing metabolic (e.g., lipid and cholesterol metabolism) related diseases, conditions and disorders, reducing the risk of said metabolic related diseases, conditions and disorders, treating and / or improving said metabolic related diseases, conditions and disorders are disclosed.